Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mesoblast Limited | ASX:MSB | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.125 | 8.31% | 1.63 | 1.65 | 1.68 | 1.6475 | 1.50 | 1.52 | 7,162,740 | 07:50:00 |
From Nov 2023 to Nov 2024
By Dean Seal
Mesoblast said regulators have granted their rare pediatric disease designation to its cell therapy Revascor for children with hypoplastic left heart syndrome.
The Australian biopharmaceutical company said Thursday that the special status from the Food and Drug Administration is granted for serious or life-threatening diseases that primarily affect children.
If the biologics licensing application for Revascor is approved, Mesoblast may now be eligible to receive a priority-review voucher from the FDA that can be used on any subsequent marketing application or transferred to a third party, the company said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 18, 2024 19:13 ET (00:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Mesoblast Chart |
1 Month Mesoblast Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
